Bluefin Biomedicine

Bluefin Biomedicine develops next-generation antibody-based therapeutics to improve the survival and quality of life of cancer patients. They use novel protein detection methods to investigate complex tumors and identify antigens that can be effectively targeted. Proprietary proteomics, transcriptomics, and bioinformatics methods help select antigens to include in their therapeutic antibody development portfolio. Their overall mission is to fill the unmet needs of cancer patients. Bluefin Biomedicine was founded in 2016 by Dr. Michael J Comb, creator of the first phospho-specific antibodies.

Jobs: